IMT1B treatment blunted cell proliferation in both SCN prostate and lung cancer cell lines with approximately twice the potency in the POU2F3/ASCL2 subtype (Fig. 4A and SI Appendix, Fig. S9A). This evidence concerns the gene ASCL2 and lung carcinoma.